share_log

RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $128

Benzinga ·  Jan 11 11:08

RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $119 to $128.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment